Mitesh

From 1 September 2025,  Dydrogesterone 10mg tablets (Nalvee®) has been added to the list of medicines covered by the HRT prepayment certificate (HRT PPC). This change has been reflected in Part XVI of the September 2025 Drug Tariff and on the NHSBSA’s website. Community Pharmacy England has also updated its HRT medicines list to reflect the [...]

The post Dydrogesterone 10mg tablets (Nalvee®) added to the HRT PPC medicines list appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the June and July 2025 reimbursement prices for the following products, to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed [...]

The post Retrospective reimbursement prices for June and July 2025 appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the June and July 2025 reimbursement prices for the following products, to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed [...]

The post Retrospective reimbursement prices for June and July 2025 appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) Date issued: 14 August 2025 Drug Alert Number: EL(25)A/40 Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information. DMRC reference number: DMRC-35838218 Marketing Authorisation [...]

The post MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) appeared first on Community Pharmacy England.

Dapagliflozin 5mg and 10mg tablets will be moving from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. Currently, all branded and generically written prescriptions [...]

The post Dapagliflozin tablets – changes to reimbursement from September 2025 appeared first on Community Pharmacy England.